Introduction
============

A large panel of monoclonal antibodies (mAbs) is currently approved by the US Food and Drug Administration (FDA) and other international regulatory agencies, including the European Medicines Agency (EMA), for the treatment of conditions as diverse as autoimmune diseases and cancer.[@R1]^,^[@R2] For illustrative purposes, antineoplastic mAbs can be subdivided into 2 large groups: (1) tumor-targeting mAbs, which directly bind to malignant cells or intercept trophic signals delivered by the tumor stroma;[@R2] and (2) immunostimulatory mAbs, which operate by interacting with (hence modulating the function of) components of the immune system.[@R3]^-^[@R5]

As we have discussed in previous issues of *OncoImmunology*,[@R6]^-^[@R8] the therapeutic potential of tumor-targeting mAbs may or may not involve immune effectors. Thus, while some of these molecules, such as the vascular endothelial growth factor (VEGF)-specific IgG1 bevacizumab,[@R9]^,^[@R10] mainly exert antineoplastic effects by inhibiting pro-survival or mitogenic signaling pathways, others, such as the CD20-targeting IgG1 rituximab,[@R11]^-^[@R13] near-to-completely rely on effector mechanisms of innate immunity, including antibody-dependent cell-mediated cytotoxicity (ADCC),[@R2]^,^[@R14]^-^[@R17] antibody-dependent cellular phagocytosis (ADCP),[@R18] and complement-dependent cytotoxicity (CDC).[@R19]^,^[@R20] Of note, some tumor-targeting mAbs, such as cetuximab, a chimeric IgG1 specific for the epidermal growth factor receptor (EGFR),[@R21]^,^[@R22] appear to inhibit tumor growth via both cancer cell-autonomous and immune system-dependent mechanisms.[@R23]^-^[@R26] In addition, tumor-targeting mAbs can be harnessed as carriers for the selective delivery to malignant cells of toxins or radionuclides. This is the case of the CD20-targeting molecules ^90^Y-ibritumomab tiuxetan and ^131^I-tositumomab, which are currently approved for the treatment of non-Hodgkin's lymphoma (NHL).[@R27]^,^[@R28]

The efficacy of immunostimulatory mAbs invariably relies on the elicitation of a novel or on the reactivation of a pre-existing immune response against malignant cells.[@R3]^-^[@R5] So far, this has been achieved through three general strategies: (1) the blockade of inhibitory receptors such as cytotoxic T lymphocyte-associated protein 4 (CTLA4)[@R29]^-^[@R31] and programmed cell death 1 (PDCD1, best known as PD-1),[@R32]^-^[@R36] both of which are expressed by activated T lymphocytes, or various members of the killer cell immunoglobulin-like receptor (KIR) family, which are found on the surface of natural killer (NK) cells;[@R37]^-^[@R40] (2) the activation of co-stimulatory receptors such as tumor necrosis factor receptor superfamily, member 4 (TNFRSF4, best known as OX40)[@R41]^-^[@R44] and TNFRSF18 (best known as GITR),[@R45]^,^[@R46] which are expressed by activated CD4^+^ and CD8^+^ T cells; (3) the neutralization of soluble immunosuppressive factors, such as transforming growth factor β1 (TGFβ1) ([Table 1](#T1){ref-type="table"}).[@R47]^-^[@R51]

###### **Table 1.** Immunostimulatory mAbs currently in clinical development

  ----------------------------------------------------------------------------------------------------------------------------------
  Target(s)         mAb             Aliases                       Isotype        Source      Activity     Owner
  ----------------- --------------- ----------------------------- -------------- ----------- ------------ --------------------------
  CD27              CDX-1127        1F5                           n.a.           Human       Agonist      Celldex

  CD40              Chi Lob 7/4     \-                            IgG1           Chimeric    Agonist      Cancer Research UK

                    CP-870,893      \-                            IgG2           Human       Agonist      Pfizer

                    Dacetuzumab     SGN-40\                       IgG1           Humanized   Agonist      Seattle Genetics
                                    huS2C6                                                                

                    Lucatumumab     HCD122                        IgG1           Human       Agonist      Novartis Pharmaceuticals

  CD274\            BMS-936559      MDX-1105                      IgG4           Human       Antagonist   Bristol--Myers Squibb
  (PD-L1, B7-H1)                                                                                          

                    MEDI4736        \-                            IgG1           Human       Antagonist   Medimmune

                    MPDL3280A       RG7446                        IgG1           Human       Antagonist   Genentech (Roche)

                    MSB0010718C     \-                            n.a.           Human       Antagonist   Serono (Merck)

  CTLA4             Ipilimumab      BMS-734016\                   IgG1κ          Human       Antagonist   Bristol--Myers Squibb
                                    MDX-010\                                                              
                                    MDX-101\                                                              
                                    Yervoy^®^                                                             

                    Tremelimumab    CP-675,206\                   IgG2           Human       Antagonist   Pfizer
                                    Ticilimumab                                                           

  KIR               IPH2101         1--7F9                        IgG4           Human       Antagonist   Innate Pharma

                    Lirilumab       BMS-986015\                   IgG4           Human       Antagonist   Bristol--Myers Squibb
                                    IPH2102                                                               

  PDCD1\            AMP-224         \-                            IgG1 chimera   Human       Antagonist   Amplimmune\
  (PD-1)                                                                                                  (Medimmune, AstraZeneca)

                    Lambrolizumab   MK-3475                       IgG4           Humanized   Antagonist   Merck

                    Nivolumab       BMS-936558 MDX1106 ONO-4538   IgG4           Human       Antagonist   Bristol--Myers Squibb

                    Pidilizumab     CT-011                        IgG1κ          Humanized   Antagonist   CureTech

  MHCII             IMP321          \-                            IgG1 chimera   Human       Agonist      Immutep

  PDCD1LG2\         rHIgM12B7       \-                            IgM            Human       Agonist      Mayo Foundation
  (PD-L2, B7-DC)                                                                                          

  TGFβ1             Fresolimumab    GC1008                        IgG4κ          Human       Antagonist   Sanofi--Aventis

  TNFRSF4\          9B12            \-                            IgG1           Murine      Agonist      AgonOx
  (OX40)                                                                                                  

                    MEDI6469        \-                            n.a.           Murine      Agonist      Medimmune\
                                                                                                          (AstraZeneca)

  TNFRSF9\          Urelumab        BMS-663513                    IgG4           Human       Agonist      Bristol-Myers Squibb
  (CD137, 4--1BB)                                                                                         

                    PF-05082566     \-                            IgG2           Human       Agonist      Pfizer

  TNFRSF18\         TRX518          \-                            IgG1           Humanized   Agonist      Tolerex
  (GITR)                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CTLA4, cytotoxic T lymphocyte-associated protein 4; KIR, killer cell immunoglobulin-like receptor; mAb, monoclonal antibody; MHCII, MHC Class II; n.a., not available; PDCD1, programmed cell death 1; PDCD1LG2, PDCD1 ligand 2; TGFβ1, transforming growth factor β1; TNFRSF, tumor necrosis factor receptor superfamily.

At odds with their tumor-targeting counterparts, which have attracted attention as potential anticancer agents as early as in the 1980s,[@R52]^-^[@R55] immunostimulatory mAbs have been the focus of intensive preclinical and clinical investigation only with the advent of the 21st century. At least in part, this relates to the fact that tumors have long been considered as immunologically silent entities, a notion that begun to change only in the late 1990s, thanks to the theoretical foundations provided by Polly Matzinger's "danger theory."[@R56]^,^[@R57] In spite of such a delayed kickoff, however, the clinical development of immunostimulatory antibodies has proceeded at a rapid pace, culminating in 2011 with the approval of ipilimumab, a fully human CTLA4-targeting IgG1κ also known as MDX-010, MDX-101, and BMS-734016 (now commercialized by Bristol--Myers Squibb under the trade mark Yervoy^®^), for use in patients with unresectable or metastatic melanoma.[@R58]^-^[@R60] Ipilimumab nowadays represents the sole immunostimulatory mAb licensed by regulatory agencies for use in cancer patients, whereas no less than 14 tumor-targeting mAbs are currently employed in the clinic as part of FDA-approved immunotherapeutic regimens.[@R1]^,^[@R2]^,^[@R8] This said, starting with the late 2000s, promising results have also been obtained in clinical trials investigating the safety and therapeutic profile of other immunostimulatory mAbs, including (1) the PD-1-targeting molecules nivolumab, a human IgG4 also known as BMS-936558, MDX-1106, and ONO-4538,[@R61]^-^[@R64] and lambrolizumab, a humanized IgG4 also known as MK-3475;[@R65] (2) BMS-936559 (also known as MDX-1105), a human IgG4 that targets the PD-1 ligand CD274 (best known as PD-L1);[@R66] and (3) the CD40 agonist mAbs CP-870,893 (a human IgG2),[@R67] and dacetuzumab, a humanized IgG1 also known as SGN-40 and huS2C6.[@R68]^,^[@R69]

Fully reflecting their immunostimulatory nature, mAbs may provoke immune reactions against self antigens that, at least potentially, may result in a life-threatening functional and/or structural damage to healthy tissues.[@R3]^,^[@R4] However, these reactions most often fail to reach a clinically meaningful amplitude and can be controlled with corticosteroids or other immunosuppressants.[@R3]^,^[@R4] Thus, immunostimulatory mAbs stand out as a relatively safe and well tolerated immunotherapeutic regimen, most frequently causing mild and controllable adverse effects including (but not limited to) skin rashes, pruritus, fatigue, nausea, and diarrhea.[@R3]^,^[@R4] As a standalone exception, urelumab (also known as BMS-663513), which operates as an agonist of the co-stimulatory receptor TNFRSF9 (best known as CD137 or 4--1BB), has been associated with severe hepatotoxicity (in particular when employed at high doses).[@R70]^,^[@R71]

We have summarized recent advances on the clinical use of tumor-targeting mAbs in the latest issue of *OncoImmunology*.[@R8] Here, along the lines of our monthly Trial Watch series,[@R72]^-^[@R75] we will restrict our focus on immunostimulatory antibodies, discussing the results of clinical trials published in the last 14 mo and commenting on studies launched in the same period to evaluate the safety and efficacy of this immunotherapeutic paradigm in cancer patients.

Update on Clinical Reports
==========================

During the last 14 mo, the results of no less than 19 clinical trials investigating the therapeutic potential of immunostimulatory mAbs in cancer patients have been published in peer-reviewed scientific journals (source <http://www.ncbi.nlm.nih.gov/pubmed>). More than half of these studies involved mAbs that antagonize the delivery of inhibitory signals to immune effector cells, including the CTLA4-targeting agents ipilimumab[@R76]^-^[@R82] and tremelimumab (a human IgG2 also known as ticilimumab or CP-675,206),[@R83]^-^[@R85] the PD-1-specific mAbs nivolumab and lambrolizumab,[@R82]^,^[@R86]^,^[@R87] as well as IPH2101 (a KIR-inhibitory human IgG4 also known as 1-7F9).[@R88]^,^[@R89] In addition, 6 studies involved mAbs that directly operate as agonists for co-stimulatory receptors, including the CD40-targeting molecules dacetuzumab, CP-870,893 and lucatumumab (a human IgG1 also known as HCD122),[@R90]^-^[@R93] 9B12, a murine IgG1 that triggers OX40 signaling,[@R94] as well as IMP321, an IgG- and lymphocyte-activation gene 3 (LAG3)-based chimera that binds to, hence activating, MHC Class II molecules ([Table 2](#T2){ref-type="table"}).[@R95]

###### **Table 2.** Recently published clinical trials investigating the therapeutic profile of immunostimulatory mAbs.\*

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target               mAb                            Indication(s)                                               Phase                            Note                              Ref.
  -------------------- ------------------------------ ----------------------------------------------------------- -------------------------------- --------------------------------- ------
  CD40                 CP-870,893                     Pancreatic cancer                                           I                                In combination with gemcitabine   92

  Advanced\            I                              In combination with paclitaxel\                             90                                                                 
  solid tumors                                        and carboplatin                                                                                                                

  Dacetuzumab          DLBCL                          Pilot                                                       In combination with rituximab\   91                                
                                                                                                                  and gemcitabine                                                    

  Lucatumumab          CLL                            I                                                           As single agent                  93                                

  MM                   I                              As single agent                                             108                                                                

  CTLA4                Ipilimumab                     Melanoma                                                    I                                In combination with vemurafenib   78

  I                    Combined with nivolumab        82                                                                                                                             

  III                  As single agent or combined\   76                                                                                                                             
                       with dacarbazine                                                                                                                                              

  Pancreatic cancer    Ib                             As single agent or combined\                                80                                                                 
                                                      with a GM-CSF-secreting vaccine                                                                                                

  Prostate carcinoma   I/II                           In combination with a GM-CSF-secreting allogeneic vaccine   77                                                                 

  I/II                 Combined with GM-CSF           81                                                                                                                             

  SCLC                 II                             In combination with paclitaxel\                             79                                                                 
                                                      and carboplatin                                                                                                                

  Tremelimumab         Melanoma                       I                                                           As single agent                  83                                

  I                    In combination with the\       85                                                                                                                             
                       TLR9 agonist PF-3512676                                                                                                                                       

  III                  As single agent                84                                                                                                                             

  KIR                  IPH2101                        AML                                                         I                                As single agent                   88

  MM                   I                              As single agent                                             89                                                                 

  MHCII                IMP321                         Pancreatic carcinoma                                        I                                In combination with gemcitabine   95

  PDCD1\               Lambrolizumab                  Melanoma                                                    I                                As single agent                   87
  (PD-1, CD279)                                                                                                                                                                      

  Nivolumab            Melanoma                       I                                                           Combined with ipilimumab         82                                

  Advanced\            I                              As single agent                                             86                                                                 
  solid tumors                                                                                                                                                                       

  TNFRSF4\             9B12                           Advanced\                                                   I                                As single agent                   94
  (OX40)                                              solid tumors                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTLA4, cytotoxic T lymphocyte-associated protein 4; DLBCL, diffuse large B-cell lymphoma; GM-CSF, granulocyte macrophage colony-stimulating factor; KIR, killer cell immunoglobulin-like receptor; mAb, monoclonal antibody; MHCII, MHC Class II; MM, multiple myeloma; PDCD1, programmed cell death 1; SCLC, small cell lung carcinoma; TLR9, Toll-like receptor 9; TNFRSF, tumor necrosis factor receptor superfamily. \*between 2012, October 1st and the day of submission.

Ipilimumab has recently been tested (1) together with the BRAF inhibitor vemurafenib in patients with metastatic melanoma bearing a BRAF V600 mutation;[@R78] (2) combined with paclitaxel (a microtubular inhibitor and hyperploidizing agent of the taxane family)[@R96]^,^[@R97] and carboplatin (a second-generation platinum derivative)[@R98]^,^[@R99] as first-line therapy in subjects bearing extensive small-cell lung cancer lesions;[@R79] (3) alone or in combination with a granulocyte macrophage colony-stimulating factor (GM-CSF)-secreting allogeneic vaccine[@R100]^,^[@R101] in pancreatic ductal adenocarcinoma patients;[@R80] and (4) as part of a nivolumab-based immunotherapeutic regimen in patients with advanced melanoma.[@R82] In addition, (1) Sherrill and colleagues evaluated the quality-adjusted survival of patients enrolled in study CA184024, a multinational, randomized, double-blind, Phase III trial testing dacarbazine (an alkylating agent currently approved by the US FDA for the treatment of Hodgkin's lymphoma and melanoma) alone vs. dacarbazine plus ipilimumab in subjects with previously untreated metastatic melanoma;[@R59]^,^[@R76] (2) Santegoets and collaborators performed an exploratory T-cell monitoring study in the context of Phase I/II dose escalation/expansion trial testing ipilimumab plus a GM-CSF-secreting allogeneic vaccine in prostate carcinoma patients;[@R77] and (3) Kwek and co-authors monitored the humoral immune responses elicited by the co-administration of ipilimumab and a fixed dose of GM-CSF[@R102]^,^[@R103] in subjects with prostate cancer.[@R81] In these clinical settings, ipilimumab-based immune(chemo)therapy was well tolerated and associated with promising clinical responses,[@R79]^,^[@R80]^,^[@R82] with a single exception.[@R78] Indeed, in 2 distinct cohorts of melanoma patients, the co-administration of ipilimumab and vemurafenib at full approved doses was associated with grade 3 elevations in circulating alanine aminotransferase (ALT) and aspartate aminotransferase (AST).[@R78] Although such hepatotoxic effects were asymptomatic and reversible upon the temporary discontinuation of treatment or the administration of glucocorticoids, this Phase I clinical trial was promptly closed to further patient accrual.[@R78]

The clinical potential of tremelimumab, employed as a standalone therapeutic intervention or combined with the Toll-like receptor 9 (TLR9) agonist PF-3512676,[@R104]^-^[@R106] has recently been assessed in patients affected by metastatic melanoma[@R83]^-^[@R85] or other advanced neoplasms.[@R85] In the context of a Phase I clinical trial, the combination of tremelimumab with PF-3512676 was well tolerated, but evoked measurable clinical responses in 2 out of 21 patients only.[@R85] Along similar lines, in the context of a large, randomized, Phase III study, no statistically significant survival advantage could be documented in metastatic melanoma patients receiving tremelimumab vs. standard-of-care chemotherapy, although response duration (measured from the time of randomization) was significantly longer in the tremelimumab arm.[@R84] Based on such a lack of efficacy, the A3671009 study (NCT00257205) has been discontinued.[@R107]

The safety and efficacy of PD-1-targeting mAbs have recently been investigated in 2 distinct cohorts of melanoma patients, receiving either lambrolizumab as a single agent in the context of a Phase I clinical trial (NCT01295827),[@R87] or nivolumab coupled to ipilimumab, again as part of a Phase I study (NCT01024231).[@R82] In addition, the long-term therapeutic potential of nivolumab given as a standalone intervention has been assessed in a mixed patient cohort, encompassing melanoma, renal cell carcinoma as well as colorectal carcinoma patients.[@R86] In these settings, the administration of PD-1-targeting mAbs alone was associated with relatively mild (grade 1 or 2) side effects.[@R86]^,^[@R87] Conversely, the co-administration of nivolumab and ipilimumab provoked grade 3 or 4 adverse reactions in a consistent proportion of melanoma patients.[@R82] Still, (1) such side effects were qualitatively similar to those previously associated with either nivolumab or ipilimumab monotherapy and were generally reversible; and (2) the combined inhibition of CTLA4- and PD-1-dependent immunosuppression was associated with an objective response in 53% of patients, invariably manifesting with a reduction in tumor burden of 80% or more.[@R82]

The clinical potential of mAbs directly targeting NK cells, rather than T lymphocytes, has recently been assessed in patients affected by acute myeloid leukemia (EUDRACT 2005--005298--31)[@R88] or relapsed/refractory multiple myeloma (NCT00552396).[@R89] In both these Phase I sequential-cohort dose-escalation studies, IPH2101 was administered as a single agent, provoking limited side effects at doses that fully inhibit KIRs.[@R88]^,^[@R89]

Finally, the safety and efficacy of immunostimulatory mAbs that operate as agonists for co-stimulatory receptors have recently been investigated (invariably in Phase I settings) (1) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory multiple myeloma, receiving lucatumumab as a single agent in the context of sequential-cohort dose-escalation studies;[@R93]^,^[@R108] (2) in subjects affected by advanced pancreatic ductal adenocarcinoma, who were treated with CP-870,893 plus gemcitabine-based chemotherapy;[@R92] (3) in individuals bearing advanced solid tumors, receiving CP-870,893 coupled to carboplatin and paclitaxel;[@R90] (4) in patients with relapsed/refractory diffuse large B-cell lymphoma, who were given dacetuzumab in combination with rituximab and gemcitabine;[@R91] (5) in individuals bearing advanced neoplasms, receiving 9B12 in combination with various adjuvants (NCT01644968);[@R94] and (6) in patients with advanced pancreatic adenocarcinoma, receiving IMP321 plus gemcitabine-based chemotherapy.[@R95] Globally, these immunostimulatory mAbs were well tolerated but exerted limited clinical efficacy.[@R90]^-^[@R95]^,^[@R108]

In summary, the results of the clinical studies reported above suggest that immunostimulatory mAbs are well tolerated by cancer patients, especially when administered as standalone interventions, yet elicit limited clinical responses in these conditions. Conversely, combinatorial approaches such as the co-administration of nivolumab and ipilimumab are associated not only with an increased incidence and severity of adverse effects, but also with improved clinical activity.[@R82]

Update on Clinical Trials Testing Immunostimulatory Monoclonal Antibodies
=========================================================================

When this Trial Watch was being redacted (November 2013), official sources listed 60 clinical trials launched after 2012, October 1st to evaluate the therapeutic profile of immunostimulatory mAbs in cancer patients (source <http://www.clinicaltrials.gov>).

For obvious advantages related to its approval status, more than half (36) of these studies aim at investigating the clinical profile of ipilimumab, either as a standalone intervention or combined with radiotherapy, conventional chemotherapeutics, targeted anticancer drugs or other immunostimulatory agents. In particular, ipilimumab is being tested as part of immunochemotherapeutic or immunoradiotherapeutic regimens in melanoma patients (NCT01701674; NCT01703507; NCT01708941; NCT01709162; NCT01715077; NCT01730157; NCT01740297; NCT01740401; NCT01767454; NCT01769222; NCT01783938; NCT01789827; NCT01810016; NCT01827111; NCT01838200; NCT01844505; NCT01856023; NCT01866319; NCT01879306), the sole oncological indication for which this CTLA4-targeting mAb is licensed by regulatory agencies, as well as in cohorts of individuals affected by various hematological malignancies (NCT01729806; NCT01757639; NCT01769222; NCT01822509; NCT01896999; NCT01919619), prostate carcinoma (NCT01804465; NCT01832870), head and neck cancer (NCT01860430; NCT01935921), non-small cell lung carcinoma (NSCLC) (NCT01820754), cervical carcinoma (NCT01711515), Merkel cell carcinoma (NCT01913691), pancreatic cancer (NCT01896869), colorectal carcinoma (NCT01769222), and various advanced/metastatic solid tumors (NCT01738139; NCT01750580; NCT01750983; NCT01928394). Alongside, the safety and efficacy of the other CTLA4-targeting mAb tremelimumab are being assessed in cohorts of malignant mesothelioma patients, receiving tremelimumab as a single agent (NCT01843374), liver cancer patients, who are treated with a combination of tremelimumab and trans-arterial catheter chemoembolization or radiofrequency ablation (NCT01853618), and subjects affected by various solid neoplasms, who are given tremelimumab plus MEDI4736 (a human IgG1 specific for PD-L1) (NCT01975831). Of note, MEDI4736 as well as two other PD-L1 targeting mAbs, namely MPDL3280A (a human IgG1 also known as RG7446) and MSB0010718C, are being investigated also as standalone therapeutic interventions in cohorts of patients affected by NSCLC (NCT01846416; NCT01903993) or various advanced solid neoplasms (NCT01772004; NCT01938612; NCT01943461) ([Table 3](#T3){ref-type="table"}).

###### **Table 3.** Clinical trials recently launched to evaluate the therapeutic profile of immunostimulatory mAbs.\*

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  mAb                          Target(s)         Indication(s)                                          Phase                                                        Status        Note                         Ref.
  ---------------------------- ----------------- ------------------------------------------------------ ------------------------------------------------------------ ------------- ---------------------------- -------------
  Anti-OX40                    TNFRSF4\          Breast carcinoma                                       I/II                                                         Recruiting    Combined with SBRT           NCT01862900
                               (OX40)                                                                                                                                                                           

  Ipilimumab                   CTLA4             AML\                                                   I                                                            Recruiting    As single agent              NCT01757639
                                                 MDS                                                                                                                                                            

  Cervical\                    I                 Recruiting                                             Combined with cisplatin\                                     NCT01711515                                
  carcinoma                                                                                             and radiation therapy                                                                                   

  CRC\                         I/II              Recruiting                                             Combined with radiation therapy                              NCT01769222                                
  Lymphoma\                                                                                                                                                                                                     
  Melanoma                                                                                                                                                                                                      

  Hematological malignancies   I                 Recruiting                                             As single agent                                              NCT01822509                                

  HNC                          I                 Recruiting                                             Combined with cetuximab\                                     NCT01860430                                
                                                                                                        and radiation therapy                                                                                   

  I                            Recruiting        Combined with cetuximab\                               NCT01935921                                                                                             
                                                 and radiation therapy                                                                                                                                          

  Hodgkin\'s\                  I                 Not yet\                                               Combined with\                                               NCT01896999                                
  lymphoma                                       recruiting                                             brentuximab vedotin                                                                                     

  Leukemia\                    n.a.              Not yet\                                               Combined with lenalidomide                                   NCT01919619                                
  Lymphoma                                       recruiting                                                                                                                                                     

  Lymphoma                     I                 Recruiting                                             Combined with rituximab                                      NCT01729806                                

  Melanoma                     n.a.              Not yet\                                               As single agent                                              NCT01715077                                
                                                 recruiting                                                                                                                                                     

  n.a.                         Not yet\          In the context of ^99^Tc-based\                        NCT01789827                                                                                             
                               recruiting        imaging procedures                                                                                                                                             

  n.a.                         Recruiting        Followed by lymphodepletion,\                          NCT01701674                                                                                             
                                                 TIL infusion and IL-2                                                                                                                                          

  0                            Recruiting        Combined with radioembolization                        NCT01730157                                                                                             

  I                            Recruiting        Combined with SRS or WBRT                              NCT01703507                                                                                             

  I                            Recruiting        Combined with dabrafenib ± trametinib                  NCT01767454                                                                                             

  I                            Recruiting        Combined with NY-ESO-1-targeting vaccine ± montanide   NCT01810016                                                                                             

  I                            Recruiting        Combined with BCG                                      NCT01838200                                                                                             

  I/II                         Recruiting        As single agent or combined\                           NCT01740297                                                                                             
                                                 with oncolytic virotherapy                                                                                                                                     

  II                           Active\           Combined with cyclophosphamide                         NCT01740401                                                                                             
                               not recruiting                                                                                                                                                                   

  II                           Not yet\          As single agent                                        NCT01879306                                                                                             
                               recruiting                                                                                                                                                                       

  II                           Recruiting        As single agent or combined\                           NCT01708941                                                                                             
                                                 with IFNα-2b                                                                                                                                                   

  II                           Recruiting        As single agent                                        NCT01709162                                                                                             

  II                           Recruiting        Combined with nivolumab                                NCT01783938                                                                                             

  II                           Recruiting        Combined with paclitaxel                               NCT01827111                                                                                             

  III                          Recruiting        Combined with nivolumab                                NCT01844505                                                                                             

  III                          Recruiting        Combined with lambrolizumab                            NCT01866319                                                                                             

  IV                           Recruiting        Combined with high-dose IL-2                           NCT01856023                                                                                             

  Merkel cell\                 II                Not yet\                                               As single agent                                              NCT01913691                                
  carcinoma                                      recruiting                                                                                                                                                     

  NSCLC                        I                 Recruiting                                             Combined with carboplatin, cisplatin and paclitaxel          NCT01820754                                

  Pancreatic cancer            II                Not yet\                                               As single agent or combined\                                 NCT01896869                                
                                                 recruiting                                             with a GM-CSF-secreting vaccine                                                                         

  Prostate cancer              I                 Recruiting                                             Combined with sipuleucel-T                                   NCT01832870                                

  II                           Active\           After sipuleucel-T treatment                           NCT01804465                                                                                             
                               not recruiting                                                                                                                                                                   

  Advanced\                    I                 Recruiting                                             Combined with imatinib                                       NCT01738139                                
  solid tumors                                                                                                                                                                                                  

  I                            Recruiting        Combined with lirilumab                                NCT01750580                                                                                             

  I                            Recruiting        Combined with lenalidomide                             NCT01750983                                                                                             

  I/II                         Not yet\          Combined with nivolumab                                NCT01928394                                                                                             
                               recruiting                                                                                                                                                                       

  Lambrolizumab                PDCD1\            CRC                                                    II                                                           Recruiting    As single agent              NCT01876511
                               (PD-1, CD279)                                                                                                                                                                    

  Hematological malignancies   I                 Not yet\                                               As single agent                                              NCT01953692                                
                                                 recruiting                                                                                                                                                     

  Melanoma                     II                Active\                                                As single agent                                              NCT01704287                                
                                                 not recruiting                                                                                                                                                 

  III                          Recruiting        Combined with ipilimumab                               NCT01866319                                                                                             

  NSCLC                        II/III            Recruiting                                             As single agent                                              NCT01905657                                

  Advanced\                    I                 Recruiting                                             As single agent or combined with conventional chemotherapy   NCT01840579                                
  solid tumors                                                                                                                                                                                                  

  I                            Recruiting        As single agent                                        NCT01848834                                                                                             

  Lirilumab                    KIR               Advanced solid tumors                                  I                                                            Recruiting    Combined with nivolumab      NCT01714739

  I                            Recruiting        Combined with ipilimumab                               NCT01750580                                                                                             

  MEDI4736                     CD274\            Advanced solid tumors                                  I                                                            Not yet\      Combined with tremelimumab   NCT01975831
                               (PD-L1, B7-H1)                                                                                                                        recruiting                                 

  I                            Recruiting        As single agent                                        NCT01938612                                                                                             

  MPDL3280A                    CD274\            NSCLC                                                  II                                                           Recruiting    As single agent              NCT01846416
                               (PD-L1, B7-H1)                                                                                                                                                                   

  II                           Recruiting        As single agent                                        NCT01903993                                                                                             

  MSB0010718C                  CD274\            Advanced solid tumors                                  I                                                            Recruiting    As single agent              NCT01772004
                               (PD-L1, B7-H1)                                                                                                                                                                   

  I                            Recruiting        As single agent                                        NCT01943461                                                                                             

  Nivolumab                    PDCD1\            Melanoma                                               II                                                           Recruiting    Combined with ipilimumab     NCT01783938
                               (PD-1, CD279)                                                                                                                                                                    

  II                           Recruiting        Combined with ipilimumab                               NCT01927419                                                                                             

  III                          Recruiting        As single agent                                        NCT01721746                                                                                             

  III                          Recruiting        As single agent                                        NCT01721772                                                                                             

  III                          Recruiting        Combined with ipilimumab                               NCT01844505                                                                                             

  NSCLC                        II                Active\                                                As single agent                                              NCT01721759                                
                                                 not recruiting                                                                                                                                                 

  II                           Recruiting        Combined with azacitidine ± entinostat                 NCT01928576                                                                                             

  Advanced solid tumors        I                 Recruiting                                             Combined with lirilumab                                      NCT01714739                                

  I                            Recruiting        As single agent or combined\                           NCT01968109                                                                                             
                                                 with immunotherapy                                                                                                                                             

  I/II                         Not yet\          As single agent or combined\                           NCT01928394                                                                                             
                               recruiting        with ipilimumab                                                                                                                                                

  Pidilizumab                  PDCD1\            Glioma                                                 I/II                                                         Not yet\      As single agent              NCT01952769
                               (PD-1, CD279)                                                                                                                         recruiting                                 

  Tremelimumab                 CTLA4             HCC                                                    I                                                            Recruiting    Combined with RFA and TACE   NCT01853618

  Mesothelioma                 II                Recruiting                                             As single agent                                              NCT01843374                                

  Advanced solid tumors        I                 Not yet\                                               Combined with MEDI4736                                       NCT01975831                                
                                                 recruiting                                                                                                                                                     

  Urelumab                     TNFRSF9\          CLL\                                                   I                                                            Recruiting    Combined with rituximab      NCT01775631
                               (CD137, 4--1BB)   NHL                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AML, acute myeloid leukemia; BCG, bacillus Calmette-Guérin; CLL, chronic lymphocytic leukemia; CRC, colorectal carcinoma; CTLA4, cytotoxic T lymphocyte-associated protein 4; GM-CSF, granulocyte macrophage colony-stimulating factor; HCC, hepatocellular carcinoma; HNC, head and neck cancer; IFNα-2b, interferon α-2b; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; mAb, monoclonal antibody; MDS, myelodysplastic syndrome; n.a., not available; NHL, Non-Hodgkin\'s lymphoma; NSCLC, non-small cell lung carcinoma; PDCD1, programmed cell death 1; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; SRS, stereotactic radiosurgery; TACE, transarterial catheter chemoembolization; TIL, tumor-infiltrating lymphocyte; TNFRSF, tumor necrosis factor receptor superfamily; WBRT; whole-brain radiation therapy. \*between 2012, October 1st and the day of submission.

As a matter of fact, targeting PD-1-dependent immunosuppression currently stands out as the experimental mAb-based immunotherapeutic paradigm most intensively investigated in clinical settings. Thus, nivolumab is being tested, most often as a standalone intervention or combined with ipilimumab, in patients with melanoma (NCT01721746; NCT01721772; NCT01783938; NCT01844505; NCT01927419), NLSLC (NCT01721759; NCT01928576), glioma (NCT01952769) or other solid neoplasms (NCT01714739; NCT01928394; NCT01968109). Alongside, the safety and therapeutic profile of lambrolizumab, most frequently employed as a single agent or together with ipilimumab, are being assessed in cohorts of subjects bearing melanoma (NCT01704287; NCT01866319), NSCLC (NCT01840579; NCT01905657), hematological malignancies (NCT01953692), colorectal carcinoma with high degrees of microsatellite instability (NCT01876511), or advanced/metastatic tumors (NCT01840579; NCT01848834) ([Table 3](#T3){ref-type="table"}).

Finally, some interest is growing around the possibility to harness the antineoplastic activity of NK cell-targeting mAbs as well as mAbs that operate as agonists for co-stimulatory T-cell and NK-cell receptors. In this setting, lirilumab (a human IgG4 that antagonizes KIRs, also known as IPH2102)[@R109] is being tested in combination with ipilimumab or nivolumab for the treatment of patients bearing advanced solid malignancies (NCT01714739; NCT01750580). Moreover, the safety and therapeutic potential of the TNFRSF9-activating mAb urelumab[@R110] and a not better specified OX40-activating mAb, combined with rituximab and stereotactic body radiation, respectively,[@R6]^,^[@R7]^,^[@R111] are being assessed in cohorts of patients with CLL, NHL (NCT01775631) or metastatic breast carcinoma (NCT01862900) ([Table 3](#T3){ref-type="table"}).

As for the clinical trials listed in our previous Trial Watches dealing with this topic,[@R6]^,^[@R7] only NCT01034787 has changed status. As a matter of fact, the status of NCT01034787, a Phase 2 trial testing intravenous tremelimumab in patients affected by uveal melanoma, is no longer available because the information relative to this study has not been verified recently (source <http://www.clinicaltrials.gov>).

Concluding Remarks
==================

Similar to their tumor-targeting counterparts,[@R8] immunostimulatory mAbs are being intensively investigated for their ability to mediate therapeutically relevant antineoplastic effects. However, while tumor-targeting mAbs are designed to specifically bind to malignant, stromal or endothelial components of neoplastic lesions or to neutralize trophic signals delivered by the tumor stroma,[@R1]^,^[@R2] most immunostimulatory mAbs modulate general mechanisms that control innate and adaptive immune responses, de facto operating in a relatively unspecific manner.[@R3]^,^[@R4]

Based on this consideration, one would expect immunostimulatory mAbs to provoke more severe side effects than their tumor-targeting counterparts[@R3]^,^[@R4] and to display a therapeutic activity resembling that of other relatively unspecific immunostimulatory interventions, such as TLR agonists,[@R104]^,^[@R105]^,^[@R112]^,^[@R113] specific cytokines,[@R102]^,^[@R103] and immunogenic chemotherapeutics.[@R74]^,^[@R75]^,^[@R114]^-^[@R116] Accumulating clinical evidence actually suggests that immunostimulatory mAbs are generally well tolerated by cancer patients, in particular when administered as standalone therapeutic interventions.[@R3]^,^[@R4] Conversely, the true clinical potential of most immunostimulatory mAbs employed as single agents remains matter of debate. So far, ipilimumab (the sole immunostimulatory mAb currently approved for use in humans) has been shown to exert robust therapeutic effects only in patients affected by melanoma,[@R58]^-^[@R60] a type of tumor that (1) is considered as inherently immunogenic, and (2) at least in part, responds to other unspecific immunostimulants, including high-dose interleukin-2 and interferon α2b.[@R102]^,^[@R103] Moreover, the clinical efficacy of ipilimumab seems a unique prerogative of this mAb rather than a general feature of CTL4-targeting mAbs such as tremelimumab.[@R84] The development of immunostimulatory mAbs is in its infancy and further studies are required to obtain profound insights into the pharmacodynamics and pharmacokinetic properties of molecules that are conceived to target the same immunomodulatory receptor yet exhibit differential clinical activity. As it stands, immunomodulatory mAbs hold great promise as tools to potentiate tumor-targeting immune responses elicited by active immunotherapeutic interventions, including recombinant vaccines,[@R117]^,^[@R118] dendritic cell-based approaches,[@R100]^,^[@R101]^,^[@R119]^,^[@R120] and adoptive T-cell transfer.[@R121]^-^[@R124] The future will tell whether immunostimulatory mAbs other than ipilimumab will add to the growing list of FDA-approved anticancer immunotherapeutics.

No potential conflicts of interest were disclosed.

Authors are supported by the Ligue contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt--Schueller; Fondation de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).

Previously published online: [www.landesbioscience.com/journals/oncoimmunology/article/27297](http://www.landesbioscience.com/journals/oncoimmunology/article/27297/)

CLL

:   chronic lymphocytic leukemia

CTLA4

:   cytotoxic T lymphocyte-associated protein 4

FDA

:   Food and Drug Administration

GM-CSF

:   granulocyte macrophage colony-stimulating factor

KIR

:   killer cell immunoglobulin-like receptor

mAb

:   monoclonal antibody

NHL

:   non-Hodgkin's lymphoma

NK

:   natural killer

NSCLC

:   non-small cell lung carcinoma

TNFRSF

:   tumor necrosis factor receptor superfamily, member

TLR

:   Toll-like receptor
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